Virtue® SAB in the Treatment of Coronary ISR Trial
← catalyst calendarNCT07045194 · readout ≤ 804 d
Sponsored by Orchestra BioMed, Inc (industry) · OBIO — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
740estimated
Sites
15
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-20 | actual | When the study began enrolling |
| Primary completion | Oct 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2032 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Coronary Artery Disease
Interventions
- Device: Virtue Sirolimus AngioInfusion Balloon
- Device: AGENT™ Paclitaxel Drug-Coated Balloon
Primary outcome
what the primary-completion date above is the date OFTarget Lesion Failure (TLF) at 12 months
measured 12 months
Permalink · OBIO's whole pipeline · Catalyst calendar · Every registered study · What changed